the aid library

LIST OPTIONS

Filter

1075

Longlist of knowledge gaps in Planetary health

Royal Netherlands Academy of Arts and Sciences (2023) C2

The longlist of knowledge gaps is based on existing research agendas published in 2015 or later and expert input from reviewers of the first draft of the longlist. It only includes knowledge gaps focussing on a better understanding of the relationship between global environmental change and human h... more

External Link

Health beliefs and health seeking behavior towards lymphatic filariasis morbidity management and disability prevention services in Luangwa District, Zambia: Community and provider perspectives

Maritim, P., A. Silumbwe, J.M. Zulu, et al. (2021) C2

Lymphatic filariasis (LF) infection if untreated results in fluid accumulation in the limbs or breasts (lymphedema) or genitalia (hydrocele) that is painful and causes great discomfort. Morbidity management and disability prevention (MMDP) strategies such as surgery for hydrocele, treatment of acute... more

External Link

A review of the available therapeutic agents that target the different steps of the ebola virus life cycle

Kang Yiu Lai, Wing Yiu George Ng and Fan Fanny Cheng (2014)

Download (413)

View PDF (480)

Kenya National Cancer Treatment Protocols

Ministry of Health, Kenya Ministry of health (2019) C1

The key areas covered are diagnosis, imaging, pathology, surgery, rehabilitation, palliative care and survivorship. It emphasizes a multi-disciplinary team approach which is paramount for quality cancer care. The specific cancers covered are breast, central nervous system, gastroint... more

Download (475)

View PDF (1289)

Guidance on the use of mpox vaccines. Revised edition

Pan American Health Organisation PAHO (2024) C_WHO

Smallpox eradication was certified in 1980. Mpox has been endemic in Central and West African countries since it was first detected in 1958 . It is a zoonosis; cases are often found close to tropical rainforests where various animals carry the orthopoxvirus that causes the disease. In endemic countr... more

Download (420)

View PDF (492)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (517)

View PDF (734)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (426)

View PDF (422)

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Download (610)

View PDF (1399)

Kenya National Clinical Nutrition and Detection Reference Manual

Kenya Ministry of Health (2010) CC

Download (662)

View PDF (491)

An Assessment of Available Evidence on NCDs and their Risk Factors in Myanmar

HelpAge International Myanmar, University of Public Health and University of Medicine-2 (2016) C1

Report on Main Findings
The review encompasses three complementary components: 1) a review of published literature 2000-2015 on NCDs and their risk factors; 2) qualitative interviews with key actors engaged in NCD research in Myanmar; and 3) additional reviews of Myanmar ethical committee inqui... more

Download (1767)

View PDF (3856)

The Treatment of Diarrhoea

World Health Organization WHO (2005) C_WHO

A manual for physicians and other senior health workers. This fourth revision of the manual reflects recent clinical experience and research findings in diarrhoea case management. Compared to earlier versions, it includes revised guidelines on the management of children with acute diarrhoea using th... more

Download (310)

View PDF (375)

Targeted and selective strategies in measles and rubella vaccination campaigns: Interim guidance

World Health Organization WHO (2025) C_WHO

The World Health Organization provides regional and national strategies and operational plans that aim to support countries in work to achieve measles control and elimination. These are guided by high level frameworks including the Immunization Agenda 2030 and the Measles and Rubella Strategic Frame... more

Download (1216)

View PDF (2460)

Bad Bug Book

Food and Drug Administration (FDA) (2013)

Handbook of Foodborne Pathogenic Microorganisms and Natural Toxins

Download (1331)

View PDF (1202)

Democratic Republic of the Congo Taxometry

World Health Organization; Regional Office for Africa (2010) C_WHO

Download (1378)

View PDF (3492)

Cambodia National Immunization Program Strategic Plan 2008-2015

Ministry of Health, Cambodia (2011) CC

Download (2069)

View PDF (1244)

Managing complications in pregnancy and childbirth: a guide for midwives and doctors

World Health Organization, UNICEF, United Nations Population Fund (2017) C_WHO

2nd Edition

External Link

Covid-19 vaccines: safety surveillance manual

World Health Organization WHO (2020) C_WHO

22 December 2020 The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vaccines will be introduced. For ease of use, the man... more

Download (3973)

View PDF (3552)

Guidelines for Antenatal Care and Skilled Attendance at Birth by ANMs/LHVs/SNs

Maternal Health Division Ministry of Health and Family Welfare Government of India Maternal Health Division Ministry of Health and Family Welfare Government of India (2010) C1

For the full document see : http://nrhm.gov.in/images/pdf/programmes/maternal-health/guidelines/sba_guidelines_for_skilled_attendance_at_birth.pdf